Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.34 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382937 | 0.91 | KCNH2 (0.47) | OPRM1OPRK1KCNH2OPRD1SIRT1 | |
| SCHEMBL3379231 | 0.86 | OPRM1 (0.39) | OPRM1OPRK1KCNH2OPRD1SIRT1 | |
| SCHEMBL13617486 | 0.73 | SMN1; SMN2 (0.36) | MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL3380014 | 0.73 | PARP2 (0.41) | OPRK1KCNH2 | |
| SCHEMBL3384573 | 0.71 | SMN1; SMN2 (0.38) | MEN1ALDH1A1PKMKMT2A | |
| SCHEMBL3380030 | 0.70 | KCNH2 (0.40) | OPRM1OPRK1KCNH2OPRD1LTA4H | |
| SCHEMBL3385537 | 0.70 | LTA4H (0.37) | OPRM1OPRK1KCNH2OPRD1LTA4H | |
| SCHEMBL3381575 | 0.69 | KCNH2 (0.40) | OPRM1OPRK1KCNH2SIRT1TRPV6 | |
| SCHEMBL3379080 | 0.67 | TRPA1 (0.36) | PARP1 | |
| SCHEMBL3384979 | 0.67 | PKM (0.41) | TRPV6MEN1ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885OPRK1 3/4885KCNH2 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.